Europe Says No to Bevacizumab (Avastin) for Glioblastoma

Looks like glioblastoma will not be added as a new indication to the product labelling for bevacizumab (Avastin) in Europe.

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) considered the data and has recommended against approval of use of bevacizumab in newly diagnosed glioblastoma, specifically for use in combination with radiation and temozolomide.

Bevacizumab is already approved in the European Union for use in several tumor types, including colorectal, breast, lung, kidney, and ovarian cancer. The drug is also marketed for many cancer types elsewhere in the world, and is one of the top-selling products in the cancer field.

Fonts: Medscape